Genmab — November 2018

[bikube]

Mens vi ligger og roder rundt med kurser på Gen mellem 900 - 1000, satte JnJ igår ny ATH. De falder så idag, men det er en helt anden årsag: JnJ cannnot prevent sales of generic Zytiga. Mylan, Teva og Hikma er alle klar med godkendte midler.

[bibob]

God morgen.

[JKY_VH]

God morgen bibob:-)

[Plimsoller]

God morgen

[Raffles]

Good morning, A small study (Dara after stem cell transplant) has been withdrawn. https://clinicaltrials.gov/ct2/history/NCT03346135?A=3&B=4&C=Side-by-Side

[Helge_LarsenPI-redaktør]

Just a moment...

(www.proinvestor.com)

[E_L]

@Sukkeralf on the back of your CD3 question; did you see the resumption of the CD3xCD123 trial as shown by gentogen?
https://clinicaltrials.gov/ct2/show/NCT02715011?term=JNJ-63709178&rank=1

[Sukkeralf]

https://myelomabeacon.org/news/2018/11/21/rvd-vrd-induction-plus-transplantation-responses-survival/

[Sukkeralf]

E L yes I did but dont pay much attention to this study due to several "on hold". I seems to be uphill.........

[Sukkeralf]

obviously any data from a duobody is exciting

[Sukkeralf]

In the Q3 report Genmab mentioned that Janssen had payed for exclusivity for jet another program if I remember correctly - thats nice that they still are active and a good sign for the platform works

[Sukkeralf]

yet

[Sukkeralf]

https://myelomabeacon.org/news/2018/11/06/overall-survival-benefit-sustained-complete-response/

[Sukkeralf]

Dette taler jo lidt for at det er vigtigt at få en dybt og vedholdende respons i første behandling

[StockBull]

Morning

[StockBull]

@Tandfeen. Mon ikke de bliver over 662 mio for Q4. Tror det for de får jo højere % sats i Q4 for Darzalex royality.

[StockBull]

16% satsen bliver nok for hele Q4

[StockBull]

Derouover rykker ROW sikkert også i Q4

[Sukkeralf]

David forventede i hvert fald lidt første linie salg i Tyskland

[E_L]

@Sukkeralf ; you are posting this article in relation to MAIA, right? One would think MDs also know this, hence the twitter discussion yesterday surprised a bit... Will be an interesting discussion at ASH...